VANI — Vivani Medical, Inc.

—
Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1266806 ·
Last close
$1.24
Market Cap
$111.85M
52W High
$1.92
52W Low
$0.92
ADV30
240,620
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -6,874,000 -6,370,000 41,639,000 19,894,000 22,672,000
Mar 2026 0 — -6,817,000 -6,780,000 42,353,000 19,749,000 23,268,000
Dec 2025 0 — -6,810,000 -6,633,000 39,393,000 16,232,000 23,663,000
Sep 2025 0 — -6,725,000 -6,530,000 25,046,000 2,628,000 23,737,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-25,353,000
Investing CF
$-1,171,000
Financing CF
$33,158,000
CapEx
$-1,171,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.42
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-155,313,000
Inventory
—
Receivables
$697,000
ST Investments
—
EBIT TTM
$-27,814,000
Pretax Income TTM
$-27,087,000
Interest Exp TTM
—
Analysts
3

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -27,556,000 -26,609,000 39,393,000 23,663,000 15,730,000 -24,320,000
Dec 2024 0 -24,677,000 -23,486,000 41,561,000 23,951,000 17,610,000 -20,786,000
Dec 2023 0 -26,965,000 -25,652,000 45,797,000 25,036,000 20,761,000 -23,699,000
Dec 2022 0 -21,241,000 -13,889,000 51,130,000 6,822,000 44,308,000 -18,787,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.35

Max Pain — expiry 2026-11-20

max pain strike: $1.00 · spot: $1.25 · call oi: 1,747 · put oi: 14
Expected Move to 2026-11-20: ±$0.32 (25.60%) — implied range $0.93 – $1.57 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PYPD PolyPid Ltd. $106.03M $5.22 —
LAKE LAKELAND INDUSTRIES INC $104.28M $10.50 —
APYX Apyx Medical Corp $124.69M $2.96 —
ECOR electroCore, Inc. $100.26M $11.12 —
NTRB NutriBand Inc. $97.25M $8.00 —

News headlines (Yahoo Finance, 1h cache)

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
2026-08-06 12:00 · Yahoo
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
2026-07-15 23:02 · Yahoo
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
2026-07-14 20:03 · Yahoo
Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant
2026-07-08 11:11 · Yahoo
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
2026-07-07 11:35 · Yahoo
Vivani strikes reverse-merger agreement with ClearOne for BCI business
2026-07-03 11:40 · Yahoo
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
2026-06-25 11:30 · Yahoo
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention
2026-06-22 20:03 · Yahoo
Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026
2026-05-28 12:30 · Yahoo
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-13 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.